Tagrisso and Imfinzi are projected to generate global sales of $8bn and $7bn, respectively, by 2030, according to GlobalData.
Analyst Andrew Berens of Leerink Partners maintained a Buy rating on AstraZeneca (AZN – Research Report), retaining the price target of ...
Even before the FDA's recent approval of Dato-DXd in breast cancer, analysts predicted sales of the antibody-drug conjugate ...
The clearance of Datroway comes months after the companies narrowed approval plans in lung cancer and opens up a market ...
On Friday, the U.S. Food and Drug Administration (FDA) approved AstraZeneca Plc’s (NASDAQ:AZN) Datroway (datopotamab ...
NDAQ:AZN) AstraZeneca PLC Is Being Sued For Securities Law Violations And Affected Shareholders Are Urged To Contact The Schall Law Firm ...
DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.
AstraZeneca PLC ADR closed 22.49% short of its 52-week high of $87.68, which the company reached on August 30th.
AstraZeneca has overhauled its local management in China, replacing Michael Lai with Alex Lin as the country's general ...
Sachin Jain, an analyst from Bank of America Securities, reiterated the Buy rating on AstraZeneca (AZN – Research Report). The associated price ...
From accelerating drug development and clinical trials to supercharging collaboration, machine learning-enhanced healthcare ...
AstraZeneca PLC AZN shares rallied 2.39% to £110.52 Tuesday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100 Index UKX rising 0.33% to 8,548.29.